In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma.

Marc-Eric HalatschAnnika DwucetCarl Julius SchmidtJulius MühlnickelTim HeilandKatharina ZeilerMarkus D SiegelinRichard Eric Kast Georg Karpel-Massler

Published in: Pharmaceuticals (Basel, Switzerland) (2021)

CUSP9v3 displays a strong anti-proliferative and anti-migratory activity in vitro and seems to be safe to apply to patients. These data have prompted further investigation of CUSP9v3 in a phase Ib/IIa clinical trial (NCT02770378).

Keyphrases

clinical trial
ejection fraction
newly diagnosed
mental health
open label
electronic health record
study protocol
big data
machine learning
chronic kidney disease
drug induced
data analysis